Stock Information
Financial Reports
News
Presentations and Events
Corporate Governance
FAQs
Analyst Coverage
2010
|
2009
|
2008
|
2007
| 2006 |
2005
Keyword Search
Date
Title
12/11/06
Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel Antifolate PDX in Patients with Peripheral T-Cell Lymphoma
11/20/06
Allos Therapeutics Added to NASDAQ Biotech Index
11/10/06
Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates Decreased Incidence of Stomatitis With Vitamin Pre-Treatment and Weekly Dosing Schedule
11/09/06
Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas at the 2006 American Society of Hematology Annual Meeting
11/06/06
Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy
11/03/06
Allos Therapeutics Reports Third Quarter 2006 Financial Results
11/01/06
Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3
10/31/06
Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific Conferences
10/23/06
Allos Therapeutics Announces ENRICH Trial Update
10/03/06
Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-cell Lymphoma
08/29/06
Allos Therapeutics to Present at Upcoming Investor Conferences
08/29/06
Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-cell Lymphoma
08/28/06
Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of EFAPROXYN(TM) in Women with Brain Metastases Originating from Breast Cancer
08/07/06
Allos Therapeutics Reports Second Quarter 2006 Financial Results
08/02/06
Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Patients with Peripheral T-cell Lymphoma
07/26/06
FDA Grants Orphan Drug Designation to Allos Therapeutics' Novel Antifolate PDX for the Treatment of T-cell Lymphoma
06/14/06
Retrospective Analysis of Allos Therapeutics' Phase 3 REACH Study Finds Positive Correlation between Patient Outcomes and EFAPROXYN(TM) (efaproxiral) Exposure in Patients with Brain Metastases from Breast and Non-Small Cell Lung Cancers
06/13/06
Allos Therapeutics Files Shelf Registration Statement
06/07/06
Allos Therapeutics to Present at the 2006 Needham & Company Biotechnology Conference
06/05/06
Allos Therapeutics Appoints James V. Caruso as Chief Commercial Officer
06/05/06
Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts
05/25/06
Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350
05/09/06
Allos Therapeutics Reports First Quarter 2006 Financial Results
04/04/06
Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial
03/10/06
Allos Therapeutics Appoints Paul L. Berns as President and CEO
03/06/06
Allos Therapeutics Reports 2005 Financial Results
03/01/06
Allos Therapeutics to Present at the 2006 Cowen Healthcare Conference
02/14/06
Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Models of Human Non-Hodgkin's Lymphoma
02/01/06
Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference
01/16/06
Allos Therapeutics Announces CEO Succession Plans
01/03/06
Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Originating From Breast Cancer
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Allos Therapeutics, Inc. has a news release. Just enter your e-mail address and click Submit.
